Sandoz CEO slams EU-wide drug price proposal, warns US tariffs will hurt patient access
LONDON (Reuters) -The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and would not solve global pricing inequities.
Richard Saynor told Reuters that the proposal - outlined in a letter to the Financial Times last week - ignores structural drivers of high drug prices in the United States.
"It made me smile, made me laugh," Saynor said of the proposal, adding that he thinks the Trump administration will succeed in driving down prices for brand-name medicines. But he said big pharmaceutical companies should not respond by hiking prices in Europe, which would hurt patient access.
Saynor argued that U.S. patients have long borne a disproportionate share of costs for innovative medicines, while large drugmakers maintain high margins.
He cited Amgen's autoimmune treatment Enbrel, which costs $70,000 per patient per year in the U.S., compared with $7,000 in Europe.
Earlier this month, Sandoz filed a U.S. antitrust lawsuit against Amgen, alleging the company blocked biosimilar competition, including Sandoz's own version. Biosimilars are near-identical copies of complex biologic drugs whose patents have expired.
Saynor said some form of U.S. price reform is inevitable, pointing to President Donald Trump's stalled plan to link drug prices to international benchmarks during his first term. Reuters reported last week that the Trump administration is again weighing such a move.
Saynor said the structure of the U.S. healthcare system - including pharmacy benefit managers - inflates prices and he likened PBMs to "leeches sucking value out of healthcare".
Generic drugs account for more than 90% of prescriptions filled in the U.S. but just 17% of spending, according to the Association for Accessible Medicines, the main generic medicines trade body. Saynor said greater use of generic and biosimilar drugs could help fund access to genuine innovation, rather than sustaining high prices for older, patent-protected medicines.
Swiss-headquartered Sandoz, which spun off from Novartis in 2023, is one of the world's largest makers of generic and biosimilar drugs. The company sells anti-infectives and generic narcotics for hospital use in the United States.
Saynor said Sandoz's North America President Keren Haruvi, who also chairs the AAM, has been meeting with White House officials nearly every week to discuss pharmaceutical imports and U.S. reliance on foreign drug production.
"They have some really tough choices to make about security of supply ... and I'm quite optimistic these are the right conversations to have ... about accessibility, affordability," he said.
He warned that if significant tariffs are imposed, Sandoz could be forced to withdraw some products from the U.S. market.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
2 minutes ago
- San Francisco Chronicle
A pause on higher tariffs for China is due to expire Tuesday. Here's what to know.
TAIPEI, Taiwan (AP) — A 90-day pause on imposing higher tariffs on China is due to expire on Tuesday and it is unclear if it will be extended. After the most recent round of China-U.S. trade talks, held late last month in Stockholm, Chinese and U.S. officials said they expected the deadline to be extended for another 90 days. The U.S. side said the decision was up to President Donald Trump. So far there has been no formal announcement about whether he will endorse an extension or push ahead with the higher tariffs. The uncertainty has left businesses in limbo and a decision to raise the import duties could jolt world markets. SILENCE FROM WASHINGTON AND BEIJING Trump has repeatedly shifted deadlines and tariff rates, and neither side has indicated what it plans for Tuesday. Extending the Aug. 12 deadline for reaching a trade agreement with China would forestall earlier threats of tariffs of up to 245%. Treasury Secretary Scott Bessent said Trump was deciding about another 90-day delay to allow time to work out details of an agreement setting tariffs on most products at 50%, including extra import duties related to illicit trade in the powerful opiate fentanyl. Higher tariffs are aimed at offsetting the huge, chronic U.S. trade deficit with China, which hit a 21-year low in July as the threat of tariffs bit into Chinese exports. It's not unusual for the U.S. to give hints on where talks stand, but it's rare for China to make announcements until major decisions are set. CHINA RESISTED CUTTING AN EARLY BARGAIN Prohibitively high tariffs on Chinese exports to the United States would put huge pressure on Beijing at a time when the Chinese economy, the world's second largest, is still recovering from a prolonged downturn in its property market. Lingering effects of the COVID-19 pandemic have left around 200 million of its workers reliant on 'gig work,' crimping the job market. Higher import taxes on small parcels from China have also hurt smaller factories and layoffs have accelerated, But the U.S. relies heavily on imports from China for all sorts of products, from household goods and clothing to wind turbines, basic computer chips, electric vehicle batteries and the rare earths needed to make them. That gives Beijing some powerful leverage in the negotiations with Washington. Even with higher tariffs, China remains competitive for many products. And its leaders are aware that the U.S. economy is only just beginning to feel the effects of higher prices from Trump's broad tariff hikes. For now, imports from China are subject to a 10% baseline tariff and a 20% extra tariff related to the fentanyl issue. Some products are taxed at higher rates. U.S. exports to China are subject to tariffs of around 30%. Before the two sides called a truce, Trump had threatened to impose 245% import duties on Chinese goods. China retaliated by saying it would hike its tariff on U.S. products to 125%. MUCH IS AT STAKE A trade war between the world's two largest economies has ramifications across the global economy, affecting industrial supply chains, demand for commodities like copper and oil and geopolitical issues such as the war in Ukraine. After a phone call with Chinese leader Xi Jinping in June, Trump said he hoped to meet with Xi later this year. That's an incentive for striking a deal with Beijing. If the two sides fail to keep their truce, trade tensions could escalate and tariffs might rise to even higher levels, inflicting still more pain on both economies and rattling world markets. Businesses would refrain from making investment commitments and hiring, while inflation would surge higher.
Miami Herald
2 minutes ago
- Miami Herald
Fed governor calls for multiple interest rate cuts
Is the long wait to cut interest rates winding down? Federal Reserve Governor Michelle Bowman wants the Fed to ditch its "wait-and-see" approach to monetary policy and begin to substantially lower interest rates starting next month. In her remarks, Bowman cited weakness in recent labor market data, plus signs that tariff inflation appears transitory, before regional senior banking leaders Aug. 9 in Colorado. Related: A divided Federal Reserve mulls interest rate cut after wild week She warned that failure to implement multiple cuts in the benchmark Federal Funds Rate this year would risk longer-term economic instability. Her speech came two days after President Donald Trump nominated long-time ally Stephen Miran to fill a temporary vacancy at the Fed, sparking concerns of increasing politicization of the independent central bank. Image source: Bloomberg/Getty Images The Federal Open Market Committee last cut the Federal Fund Rates in December 2024. Fed Chair Jerome Powell has been under heavy fire from the White House for several months to slash rates from the current 4.25% to 4.50% level. Bowman and Fed Governor Christopher Waller, Trump appointees along with Powell, dissented from the July FOMC vote to create a historic split from the other members of the 12-person panel. Seven of those members are Fed Board of Governors, the other five rotate from the heads of the regional Federal Reserve banks. Both Bowman and Waller said early signs of weakness in the labor market justified a .25-percentage-point cut. It was the first FOMC dissent since 1993. The Federal Reserve's dual mandate from Congress requires monetary policy that balances low unemployment and low inflation. The Fed uses interest rates as the benchmark tool to maintain both sides of its mandate. But there is tension between the two. Higher interest rates lower inflation but increase job losses, while lower interest rates decrease unemployment but increase inflation. Related: Federal Reserve votes on interest rates The Federal Funds Rate is the interest rate banks pay to borrow money overnight. It sets the cost of short-term borrowing - for example, the interest on credit cards, auto loans, home equity loans, and student loans. When the Fed raises rates, yields on short-term securities typically climb and push up longer-term yields like the 10-year Treasury Bond. (Investors demand higher returns to offset anticipated inflation and tighter credit conditions.) The 10-year Treasury yield is a benchmark for U.S. mortgage rates because lenders use it to price long-term loans. As the yield rises, mortgage rates usually increase, making borrowing more expensive for homebuyers. Conversely, when the yield drops, so do mortgage rates. President Trump has been demanding a 3-percentage-point rate cut, saying it is necessary to curb recession fears, ease the stagnant housing market with lower mortgages, and reduce the interest on the federal deficit. He has lashed out at the Fed chair with heated name-calling ("Too Late Powell") and other taunts. Bowman called on the FOMC to perform three interest rate cuts of .25 this year, starting with its Sept. 17 meeting. The FOMC also meets in October and December. "A proactive approach in moving policy closer to neutral, from its current moderately restrictive stance, would help avoid a further unnecessary erosion in labor market conditions and reduce the chance that the (FOMC) will need to implement a larger policy correction should the labor market deteriorate further,'' Bowman said in prepared remarks. Bowman said it appears that inflation data is heading downward toward the Fed's 2% target, signaling that price hikes from the highest U.S. tariffs in nearly a century may be a single bump and not long term. More Federal Reserve: GOP plan to remove Fed Chair Powell escalatesTrump deflects reports on firing Fed Chair Powell 'soon'Former Federal Reserve official sends bold message on 'regime change' "As I gain even greater confidence that tariffs will not present a persistent shock to inflation, I see that upside risks to price stability have diminished," Bowman said. "With underlying inflation on a sustained trajectory toward 2%, softness in aggregate demand and signs of fragility in the labor market, I think that we should focus on risks to our employment mandate," she said. Earlier in the week, Minneapolis Fed President Neel Kashkari, San Francisco Fed President Mary Daly, and Fed Governor Lisa Cook also expressed concern over new figures that show a sharp cooling in the labor market. Employers added a lower-than-expected 73,000 jobs in July, and gains in May and June were revised down by nearly 260,000, according to the Bureau of Labor Statistics. The unemployment rate inched up to 4.2% from 4.1% in June. Bob Fraser, CIO and co‑founder of Aspen Funds, oversees more than $600 million across private credit and alternative income strategies. He expressed concern about multiple rate cuts in 2025. "Weak July employment data has definitely strengthened the case for cuts," Fraser told TheStreet. He added that Atlanta Fed President Raphael Bostic recently noted that hiring revisions were significant but reiterated his expectation of only one rate cut in 2025. "All this implies that any rate cuts will likely be uneven and cautious, especially if inflation continues to prove sticky,'' he said. The CME Group's widely watched FedWatch Tool forecasts the likelihood of September rate cut at 88.9%. Related: Trump makes surprise decision on Federal Reserve The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Medscape
2 minutes ago
- Medscape
Low Disease Activity Maintained Long Term With TNF Tapering
TOPLINE: A tapering strategy for TNF inhibitors maintained low disease activity in patients with psoriatic arthritis (PsA) and those with axial spondyloarthritis (AxSpA) over 24 months. Protocol-driven tapering achieved a greater reduction in the mean dose of TNF inhibitors than routine care tapering, with both methods equally effective for disease control. METHODOLOGY: Previous 12-month results from an open-label, noninferiority, pragmatic trial (January 2019 to July 2020) conducted in the Netherlands showed that tapering of TNF inhibitors was noninferior to continued dosing for maintaining low disease activity in patients with PsA or AxSpA. Participants in the original trial (aged 16 years or older with stable low disease activity for 6 or more months) were randomly assigned to either a treat-to-target tapering strategy (intervention) or a continuation of the original dose of TNF inhibitors (control). Tapering involved extending the interval between doses, leading to doses equivalent to 100%, 66%, 50%, 33%, or 0% of the defined daily dose. This observational extension of the original trial included 114 patients (mean age, 50 years; 79 from the intervention group and 35 from the control group) with PsA (n = 58) and AxSpA (n = 56), where the intervention group continued the tapering strategy, whereas the control group could attempt tapering (routine care tapering), with treatment decisions made collaboratively by physicians and patients. The primary outcome was the difference in the proportion of patients with low disease activity at 24 months between the intervention and control groups compared against a prespecified noninferiority margin of 20%. Secondary outcomes included differences in efficacy between the intervention and control groups determined using disease activity scores at 18 and 24 months, as well as the cumulative incidence of disease flare over 24 months. TAKEAWAY: At 24 months, 67% of patients in the intervention group and 72% in the control group maintained low disease activity (adjusted difference, 5%; P = .64). Over 24 months, 89% of patients attempted tapering, with no significant differences in adverse events between groups. No difference was noted in the percentage of patients achieving low disease activity between the intervention group with protocol-driven tapering at 12 months and the control group with routine care tapering at 24 months. The cumulative incidence of disease flare was 90% over 24 months. The mean dose of TNF inhibitors increased in the intervention group from 52% to 66% of the defined daily dose from 12 months to 24 months (difference, 14%; P < .0001). However, the mean dose was lower with protocol-driven tapering in the intervention group at 12 months than with routine care tapering in the control group at 24 months (P = .0001) and lower with routine care tapering vs no tapering in the control group (P = .0007). IN PRACTICE: '[T]hese data indicate that a taper-to-target strategy is effective and leads to substantial TNF inhibitor dose reduction, but optimal execution of such a strategy in routine care is more challenging than in the context of a clinical trial,' the authors of the study wrote. 'Considering the risks and benefits of tapering, we suggest that disease activity-guided tapering could enable more optimized and personalized treatment in patients with psoriatic arthritis and axial spondyloarthritis.' SOURCE: The study was led by Amy C.D. Peeters, MD, and Celia A.J. Michielsens, MD, PhD, Sint Maartenskliniek in Nijmegen, the Netherlands. It was published online on July 24, 2025, in The Lancet Rheumatology. LIMITATIONS: Measurements for disease activity were missing at 18 and 24 months. The absence of validated flare criteria until 2022 may have led to an overestimation of flare incidence. Radiographic progression was not assessed at the 24-month follow-up. Allowing tapering in the control group during the extension phase reduced the difference between groups. DISCLOSURES: The study was funded by ReumaNederland. Some authors reported receiving grants from multiple companies including Novartis, Eli Lilly and Company, and AbbVie to their institution. One author reported receiving support for attending meetings and/or travel from Pfizer, Novartis, and UCB. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
